Breaking News
February 19, 2018 - ID Break: Clean Hands, Fewer Abx; $11 Million HIV Cure?; MenB Vax for Kids
February 19, 2018 - Patient exposure to X-rays depends on how dentists are paid
February 19, 2018 - FDA approves first treatment to reduce risk of NSCLC progression
February 19, 2018 - FDA Expands Approval of Imfinzi (durvalumab) to Reduce the Risk of Non-Small Cell Lung Cancer Progressing
February 19, 2018 - D.C. Week: Congress Passes Spending Bill
February 19, 2018 - Heart-muscle patches made with human cells improve heart attack recovery
February 19, 2018 - FDA Approves First Blood Test to Detect Concussions
February 19, 2018 - Survival Bump in Bladder Cancer with Keytruda
February 18, 2018 - Scientists describe the mechanism of heart regeneration in the zebrafish
February 18, 2018 - Scientists uncover the structure of microtubule motor proteins
February 18, 2018 - Light-activated cancer drugs without toxic side effects are closer to becoming reality
February 18, 2018 - Pioneering research could provide novel insight into how genomic information is read
February 18, 2018 - Pearls From: David Putrino, PhD
February 18, 2018 - Researchers uncover how cancer stem cells drive triple-negative breast cancer
February 18, 2018 - Morning Break: Anti-Anti-Vaxxers; Private Piercings Prohibited; A Case for Pelvic Massage
February 18, 2018 - Lower-dose radiation effective, safe for HPV+ head and neck cancer after induction chemo
February 18, 2018 - Specialist residential service for adults with autism opens in Swansea
February 18, 2018 - FDA Moves to Limit Loperamide Doses per Package
February 18, 2018 - Alcohol use disorder – Genetics Home Reference
February 18, 2018 - Autism might be better detected using new two-minute questionnaire
February 18, 2018 - Hand hygiene-intervention practices may reduce risk of infection among nursing home patients
February 18, 2018 - Researchers develop most sophisticated mini-livers to date
February 18, 2018 - Obamacare Helped More Young Women Get Prenatal Care: Study
February 18, 2018 - School-Based Program Fails to Dent Kids’ Obesity
February 18, 2018 - Research compares neural activity in children with and without autism spectrum disorder
February 18, 2018 - Poor fitness levels increase the risk dementia, concludes study
February 18, 2018 - Risk Score May Reveal if Kids are Victims of Ill-Treatment
February 18, 2018 - Adding Folic Acid to Corn Masa Flour May Prevent Birth Defects
February 18, 2018 - Acute treatment suppresses posttraumatic arthritis in ankle injury
February 18, 2018 - A Role for Budesonide in Autoimmune Hepatitis?
February 18, 2018 - Lupus patients exhibit altered cell proteins, a discovery with potential implications for diagnostics
February 18, 2018 - Muscle plays vital role in regulating heat loss from the hands
February 18, 2018 - High-tech brain scans can provide new way to define intelligence
February 18, 2018 - Study reveals the association between ultra-processed foods and cancer
February 18, 2018 - Prescription Opioid Use Tied to Higher Pneumonia Risk
February 18, 2018 - A non-invasive method to detect Alzheimer’s disease
February 18, 2018 - Deletion of specific enzyme leads to improvement in memory and cognitive functions
February 18, 2018 - Amyloid protein may be transmitted through neurosurgical instruments, study suggests
February 18, 2018 - Electric brain signals of males and females show differences
February 18, 2018 - American Heart Association commends McDonald’s for offering healthier menu in kids’ meals
February 18, 2018 - Parents Find Kids’ Weight Report Cards Hard to Swallow
February 18, 2018 - Does a Financial Conflict of Interest Ever Expire?
February 18, 2018 - Exercise can improve Alzheimer’s symptoms
February 18, 2018 - Scientists develop green chemistry method to improve pharmaceutical manufacturing efficiency
February 17, 2018 - ‘A Time Clock to a Tissue Clock’ for Acute Stroke Care
February 17, 2018 - Cancer Care Gets Personal | NIH News in Health
February 17, 2018 - Do more youth use or do youth use more?
February 17, 2018 - Eating faster linked to obesity
February 17, 2018 - Who’s Still Smoking? ACS Report Highlights Most Vulnerable Adults
February 17, 2018 - Study of smoking and genetics illuminates complexities of blood pressure
February 17, 2018 - Study reveals new link between bone cells and blood glucose level
February 17, 2018 - Children with reading challenges may have lower than expected binocular vision test results
February 17, 2018 - Mass Shootings Trigger Change for Emergency Medicine
February 17, 2018 - ECMO helps revive woman thought to be drowned
February 17, 2018 - Learning stress-reducing techniques may benefit people with epilepsy
February 17, 2018 - Shedding Pounds Before Weight-Loss Surgery a Smart Move
February 17, 2018 - FDA Approves New Cystic Fibrosis Drug Combo
February 17, 2018 - Augmented Reality helps surgeons to ‘see through’ tissue and reconnect blood vessels
February 17, 2018 - Emotional state affects operation of the entire brain instead of being restricted to specific regions
February 17, 2018 - Apalutamide Slows Metastasis in Prostate Cancer
February 17, 2018 - Kids’ well visits linked to lower appendicitis complications
February 17, 2018 - New NK cell-based immunotherapy effective against several types of leukemia
February 17, 2018 - Producing Super-Swelled Lyotropic Crystals for Drug Development
February 17, 2018 - Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
February 17, 2018 - Molecular Imaging Flags Risk of AAA Rupture
February 17, 2018 - Researchers identify risk factors for sleep apnea during pregnancy
February 17, 2018 - More work required to find the right drug dosage for pediatric patients
February 17, 2018 - Factors ID’d That Predict RA Remission with Etanercept
February 17, 2018 - A handout or a hand up? How we judge others guides how we help others
February 17, 2018 - ACR receives grant to focus on projects that reduce health disparities
February 17, 2018 - Pimavanserin Might Be Safer Alternative to Ease Dementia Psychosis
February 17, 2018 - Risks of Lung Screening Seen Outweighing Benefits in Many with Smoking History
February 17, 2018 - The impact of Hurricane Harvey on pregnant moms
February 17, 2018 - Gene editing tool used to detect cancer
February 17, 2018 - Researchers detail molecular atlas of cells that form brain’s blood vessels
February 17, 2018 - TUM scientists observe formation of myelin sheaths around nerve fibers
February 17, 2018 - Worst Flu Season Yet? | Medpage Today
February 17, 2018 - Finding the root cause of bronchiolitis symptoms
February 17, 2018 - Climbing stairs reduces hypertension and strengthens muscles
February 17, 2018 - Nature paper unveils bacterial division
Study of men with inherited DNA repair mutations opens new therapeutic avenues in prostate cancer

Study of men with inherited DNA repair mutations opens new therapeutic avenues in prostate cancer

image_pdfDownload PDFimage_print

Selected by the American Society of Clinical Oncology (ASCO) to first outing during its Genitourinary Cancers Symposium, Translating Evidence to Multidisciplinary Care, February 8 – 10 (San Francisco, USA), Joaquin Mateo, Principal Investigator of VHIO’s recently created Prostate Cancer Translational Research Group, will today reveal findings from a retrospective and international study showing for the first time that patients with inherited DNA repair mutations benefit from standard therapies in a similar way to other metastatic prostate cancer patients.

Timed to coincide with Joaquin Mateo’s presentation at this week’s ASCO meeting, these results will be published today in the prestigious journal European Urology.

Given that standard therapies traditionally target the hormonal basis of prostate cancer – as opposed to genetic mutation – the team sought to evidence whether patients with metastatic prostate cancer with identified DNA-repair gene mutations, typically found in one out of every ten of these patients, could derive similar benefit from treatment with standard of care therapies. In so doing, they aimed to establish the prognostic and predictive value of these alterations towards a more personalized stratification of patients.

Between 2005 – 2015, the most common cancer for men was prostate cancer with an estimated 1.6 million cases. Recent findings suggest that while it is relatively rare for prostate cancer to spread in the body, metastatic and aggressive prostate cancer is on the rise.

“While prostate tumors are more generally slow-growing than other cancers, the reality in Spain alone is that this disease claims the lives of 6,000 individuals every year. Translational studies aimed at better identifying which patients would most likely benefit from both standard therapies as well as novel anti-cancer approaches are critical if we are to ultimately improve outcomes for patients with metastatic disease”, observes Joaquin, first author of the study.

Until quite recently, prostate cancer was considered to be exclusively dependent on male androgens fuelling prostate cancer cell growth, and the majority of anti-cancer therapies have thus focused on tackling this tumor type from this angle. Current research is rapidly transforming the way in which prostate cancer is both considered and managed, paving the way for more effective and tailored treatment approaches.

Previous findings published in Cell in 2015 showed that between 20-25% of patients with metastatic prostate cancer had DNA-repair related mutations as well as BRCA mutations, or similar.

In 2016, Mateo and colleagues evidenced that DNA-repair gene mutations are found inherited in one out of every ten men with metastatic prostate cancer. This discovery, published in The New England Journal of Medicine, has since placed these mutations firmly under the lens in efforts aimed at benefiting an increasing number of these patients.

Additional research has therefore centered on showing whether individuals with these identified mutations could better respond to other treatments. Clinical findings also reported by Joaquin and co-collaborators from the Institute of Cancer Research – Royal Marsden NHS Foundation Trust (London, UK), revealed that some of these patients responded to PARP inhibitors, which are already approved in the case of metastatic breast cancer and ovarian cancer in carriers of mutations in BRCA.

This discovery has since led to several currently ongoing international clinical trials in prostate cancer. The next step was to analyze treatment response in these patients to establish whether this inherited genetic variation affects the efficacy of therapy.

In this latest study, results were analyzed for a total of 390 metastatic prostate cancer patients with DNA-repair gene mutations to assess response to standard treatments. Findings indicate that patients with BRCA mutations respond to these therapies in a similar way to other patients with metastatic prostate cancer patients without these mutations.

Overall survival and disease-free progression were therefore comparable and no significant differences in response rate to first-line treatment were observed. In addition, a trend toward greater overall survival was noted in those patients with mutations who had participated in studies with PARP inhibitors or platinum-based therapy.

“Since this cohort of patients is the first with long-term data available on the response to post-therapy with PARP inhibitors and platinum-based agents, our research also marks an important first. We are seeing that patients with these mutations not only benefit from standard treatments, but may also have additional therapeutic options available”, explains Joaquin.

“While our data are still preliminary, I believe that we have every reason to be optimistic about these initial results. Importantly, with several trials with PARP Inhibitors for prostate cancer currently underway at VHIO, new clinical data to emerge from these studies will hopefully further support the use of these inhibitors in the treatment of our patients”, he concludes.

Joining forces with VHIO’s Genitourinary, CNS Tumors, Sarcoma & Cancer of Unknown Primary Site Group Cancer led by Joan Carles, also located within the Vall d´Hebron Barcelona Hospital Campus, Joaquin’s Prostate Cancer Translational Research Group will pioneer research aimed at translating prostate cancer genotypes into phenotypes and a clinically-relevant classification of the disease. These teams will also seek to build a precision medicine core for prostate cancer patients.

His group’s expertise, combined with that of Joan Carles, will accelerate the translation of the use of PARP inhibitors as a more effective therapy for metastatic prostate cancer patients to the clinic. Currently open clinical studies performed at VHIO, matched to the molecular alterations and specificities detected in individual patients, are possible thanks to its renowned prescreening program, pioneered by VHIO’s Cancer Genomics and Molecular Oncology Groups, led by Ana Vivancos and Paolo Nuciforo, respectively.​

Source:

Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer

Tagged with:

About author

Related Articles